Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1993 Jul;46(7):668–671. doi: 10.1136/jcp.46.7.668

Immunophenotypic characterisation of acute leukaemia after polycythemia vera.

J M Hernández 1, A Orfao 1, M González 1, B Cuesta 1, M C López-Berges 1, M C Cañizo 1, J Ciudad 1, J F San Miguel 1
PMCID: PMC501400  PMID: 8157758

Abstract

AIMS--To analyze the immunophenotype of blast cells in patients with acute leukaemia after polycythemia vera, together with the most relevant clinical and haematological disease characteristics. METHODS--The immunophenotype was analysed in nine patients by immunofluorescence flow cytometry using a panel of 15 monoclonal antibodies. The DNA content of blast cells was determined using Vindelov's technique. RESULTS--The most relevant clinical and haematological disease characteristics included: the presence of enlarged spleen and liver by 56% and 67%, respectively; a moderate degree of leucocytosis with thrombocytopenia while haemoglobin was normal in 50% of patients. All patients received alkylating agents or hydroxyurea, or both. Interestingly, the chronic phase in patients receiving this latter drug was shorter. All cases showed a myeloid phenotype, four of them reactive only to early myeloid antigens (CD13/33); in the remaining cases the blast cells displayed granulomonocytic (CD14+, CD15+), erythroid (CD71 ), or megakaryocytic (CD61+, CD41+) markers. Coexpression of lymphoid related antigens (CD7, TdT, or CD19) was also detected. The morphological assessment of blast cells agreed with the immunophenotyping in five out of the nine cases. Blast cells from all six patients analysed displayed a diploid DNA content and the proportion of S-phase cells ranged from 0.4% to 4%. CONCLUSIONS--These findings suggest a pluripotential stem cell with myeloid commitment as the target cell of acute leukaemia after polycythemia vera.

Full text

PDF
668

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adamson J. W., Fialkow P. J., Murphy S., Prchal J. F., Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med. 1976 Oct 21;295(17):913–916. doi: 10.1056/NEJM197610212951702. [DOI] [PubMed] [Google Scholar]
  2. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976 Aug;33(4):451–458. doi: 10.1111/j.1365-2141.1976.tb03563.x. [DOI] [PubMed] [Google Scholar]
  3. Berk P. D., Goldberg J. D., Silverstein M. N., Weinfeld A., Donovan P. B., Ellis J. T., Landaw S. A., Laszlo J., Najean Y., Pisciotta A. V. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981 Feb 19;304(8):441–447. doi: 10.1056/NEJM198102193040801. [DOI] [PubMed] [Google Scholar]
  4. Bettelheim P., Lutz D., Majdic O., Paietta E., Haas O., Linkesch W., Neumann E., Lechner K., Knapp W. Cell lineage heterogeneity in blast crisis of chronic myeloid leukaemia. Br J Haematol. 1985 Mar;59(3):395–409. doi: 10.1111/j.1365-2141.1985.tb07326.x. [DOI] [PubMed] [Google Scholar]
  5. Cervantes F., Tassies D., Salgado C., Rovira M., Pereira A., Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol. 1991;85(3):124–127. doi: 10.1159/000204873. [DOI] [PubMed] [Google Scholar]
  6. Donovan P. B., Landaw S. A., Dresch C., Gartenhaus W. S., Goldberg J. D., Ellis J. T., Loeb V., Jr, Perry M. C., Petitt R. M., Pisciotta A. V. Resistance to therapy of acute leukemia developing in the course of polycythemia vera. Nouv Rev Fr Hematol. 1981;23(4):187–192. [PubMed] [Google Scholar]
  7. Ellis J. T., Peterson P., Geller S. A., Rappaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol. 1986 Apr;23(2):144–155. [PubMed] [Google Scholar]
  8. Hernández J. M., González-Sarmiento R., Martin C., González M., Sánchez I., Corral J., Orfao A., Cañizo M. C., San Miguel J. F., López-Borrasca A. Immunophenotypic, genomic and clinical characteristics of blast crisis of chronic myelogenous leukaemia. Br J Haematol. 1991 Nov;79(3):408–414. doi: 10.1111/j.1365-2141.1991.tb08048.x. [DOI] [PubMed] [Google Scholar]
  9. Hernández J. M., San Miguel J. F., González M., Orfao A., Cañizo M. C., Bascones C., Hernández J., López Borrasca A. Development of acute leukaemia after idiopathic myelofibrosis. J Clin Pathol. 1992 May;45(5):427–430. doi: 10.1136/jcp.45.5.427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kaplan M. E., Mack K., Goldberg J. D., Donovan P. B., Berk P. D., Wasserman L. R. Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin Hematol. 1986 Jul;23(3):167–171. [PubMed] [Google Scholar]
  11. Landaw S. A. Acute leukemia in polycythemia vera. Semin Hematol. 1986 Apr;23(2):156–165. [PubMed] [Google Scholar]
  12. MODAN B., LILIENFELD A. M. POLYCYTHEMIA VERA AND LEUKEMIA--THE ROLE OF RADIATION TREATMENT. A STUDY OF 1222 PATIENTS. Medicine (Baltimore) 1965 Jul;44:305–344. doi: 10.1097/00005792-196507000-00003. [DOI] [PubMed] [Google Scholar]
  13. Mertens F., Johansson B., Heim S., Kristoffersson U., Mitelman F. Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature. Leukemia. 1991 Mar;5(3):214–220. [PubMed] [Google Scholar]
  14. Najean Y., Deschamps A., Dresch C., Daniel M. T., Rain J. D., Arrago J. P. Acute leukemia and myelodysplasia in polycythemia vera. A clinical study with long-term follow-up. Cancer. 1988 Jan 1;61(1):89–95. doi: 10.1002/1097-0142(19880101)61:1<89::aid-cncr2820610115>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  15. Nand S., Messmore H., Fisher S. G., Bird M. L., Schulz W., Fisher R. I. Leukemic transformation in polycythemia vera: analysis of risk factors. Am J Hematol. 1990 May;34(1):32–36. doi: 10.1002/ajh.2830340108. [DOI] [PubMed] [Google Scholar]
  16. Orfao A., Ciudad J., González M., San Miguel J. F., García A. R., López-Berges M. C., Ramos F., Del Cañizo M. C., Ríos A., Sanz M. Prognostic value of S-phase white blood cell count in B-cell chronic lymphocytic leukemia. Leukemia. 1992 Jan;6(1):47–51. [PubMed] [Google Scholar]
  17. Parreira A., Pombo de Oliveira M. S., Matutes E., Foroni L., Morilla R., Catovsky D. Terminal deoxynucleotidyl transferase positive acute myeloid leukaemia: an association with immature myeloblastic leukaemia. Br J Haematol. 1988 Jun;69(2):219–224. doi: 10.1111/j.1365-2141.1988.tb07625.x. [DOI] [PubMed] [Google Scholar]
  18. Rosenthal D. S., Moloney W. C. Occurrence of acute leukaemia in myeloproliferative disorders. Br J Haematol. 1977 Jul;36(3):373–382. doi: 10.1111/j.1365-2141.1977.tb00661.x. [DOI] [PubMed] [Google Scholar]
  19. San Miguel J. F., Gonzalez M., Cañizo M. C., Anta J. P., Zola H., Lopez Borrasca A. Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification. Br J Haematol. 1986 Nov;64(3):547–560. doi: 10.1111/j.1365-2141.1986.tb02211.x. [DOI] [PubMed] [Google Scholar]
  20. San Miguel J. F., Hernández J. M., González-Sarmiento R., González M., Sánchez I., Orfao A., Cañizo M. C., López Borrasca A. Acute leukemia after a primary myelodysplastic syndrome: immunophenotypic, genotypic, and clinical characteristics. Blood. 1991 Aug 1;78(3):768–774. [PubMed] [Google Scholar]
  21. San Miguel J. F., Tavares de Castro J., Matutes E., Rodriguez B., Polli N., Zola H., McMichael A. J., Bollum F. J., Thompson D. S., Goldman J. M. Characterization of blast cells in chronic granulocytic leukaemia in transformation, acute myelofibrosis and undifferentiated leukaemia. II. Studies with monoclonal antibodies and terminal transferase. Br J Haematol. 1985 Feb;59(2):297–309. doi: 10.1111/j.1365-2141.1985.tb02995.x. [DOI] [PubMed] [Google Scholar]
  22. Swolin B., Weinfeld A., Westin J. A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood. 1988 Aug;72(2):386–395. [PubMed] [Google Scholar]
  23. Toh B. T., Gregory S. A., Knospe W. H. Acute leukemia following treatment of polycythemia vera and essential thrombocythemia with uracil mustard. Am J Hematol. 1988 May;28(1):58–60. doi: 10.1002/ajh.2830280113. [DOI] [PubMed] [Google Scholar]
  24. Vindeløv L. L., Christensen I. J., Nissen N. I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 1983 Mar;3(5):323–327. doi: 10.1002/cyto.990030503. [DOI] [PubMed] [Google Scholar]
  25. Wasserman L. R. The treatment of polycythemia vera. Semin Hematol. 1976 Jan;13(1):57–78. [PubMed] [Google Scholar]
  26. Weinfeld A., Westin J., Ridell B., Swolin B. Polycythaemia vera terminating in acute leukaemia. A clinical, cytogenetic and morphologic study in 8 patients treated with alkylating agents. Scand J Haematol. 1977 Sep;19(3):255–272. doi: 10.1111/j.1600-0609.1977.tb02105.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES